Get the Stockscreener App
26.42
6.49%
1.61
Immunovant Inc stock is traded at $26.42, with a volume of 3.68M.
It is up +6.49% in the last 24 hours and up +12.71% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$24.81
Open:
$24.9
24h Volume:
3.68M
Relative Volume:
2.08
Market Cap:
$4.63B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-10.08
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+15.67%
1M Performance:
+12.71%
6M Performance:
+65.75%
1Y Performance:
-4.24%
1-Day Range:
$24.46
$26.50
1-Week Range:
$22.33
$27.06
52-Week Range:
$12.72
$28.08
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.42 | 4.35B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Immunovant Raises $550 Million Through Stock Offering - TipRanks
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha
Immunovant Enters Underwriting Agreement for Stock Offering - TradingView
Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat
Immunovant announces $550 million stock offering - MSN
Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP
Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada
Immunovant announces $550 million stock offering and clinical program updates By Investing.com - Investing.com South Africa
Immunovant Announces $550 Million Stock Offering - TipRanks
Immunovant announces pricing of $550 million common stock financing - marketscreener.com
Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView
Immunovant drops 7%, prices $550M stock offering - MSN
Immunovant Prices $550 Million Stock Offering - marketscreener.com
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Globe and Mail
Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Norges Bank Buys Shares of 687,662 Immunovant, Inc. $IMVT - MarketBeat
55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A. - MarketBeat
Two Seas Capital LP Boosts Stake in Immunovant, Inc. $IMVT - MarketBeat
Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 15,000 Shares of Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 22,249 Shares of Stock - MarketBeat
Immunovant Executives Sell Shares Under Trading Plans - TradingView
Dir Fromkin Surrenders 22,249 Of Immunovant Inc [IMVT] - TradingView
Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN
Immunovant (IMVT) Stock Analysis Report | Financials & Insights - Benzinga
XTX Topco Ltd Buys New Holdings in Immunovant, Inc. $IMVT - MarketBeat
Tejara Capital Ltd Raises Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. $IMVT Shares Acquired by Geode Capital Management LLC - MarketBeat
(IMVT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
12 Best Short Squeeze Stocks to Buy Right Now - Insider Monkey
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength - MSN
Officer Geffner Files To Sell 50,000 Of Immunovant Inc [IMVT] - TradingView
Officer Geffner Files To Sell 103,897 Of Immunovant Inc [IMVT] - TradingView
Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure - Sahm
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN
Have Insiders Sold Immunovant Shares Recently? - simplywall.st
Immunovant Restructures R&D Leadership with CMO Departure - The Globe and Mail
Immunovant COO Gloria sells $298k in shares By Investing.com - Investing.com Nigeria
Immunovant COO Gloria sells $298k in shares - Investing.com
Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing - MarketScreener
Immunovant COO Gloria Melanie Sells Shares to Cover Tax Obligations - TradingView
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
[8-K] Immunovant, Inc. Reports Material Event | IMVT SEC FilingForm 8-K - Stock Titan
Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025 - marketscreener.com
How analysts rate Immunovant Inc. stock todayInsider Selling & Technical Entry and Exit Tips - newser.com
Will Immunovant Inc. stock outperform value stocksTrade Exit Summary & Weekly Breakout Watchlists - newser.com
Is Immunovant Inc. stock affected by interest rate hikesJuly 2025 Gainers & Stepwise Trade Signal Implementation - newser.com
Can swing trading help recover from Immunovant Inc. losses2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):